XL228 is a synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis.
Related Prodcuts:
Fidaxomicin; Marbofloxacin; CP-466722; TTP 22; D-64131; M344; CHIR-124; Reversine; Pralatrexate; VE-822; RI-1; SRPIN340; XL888; Rigosertib; APY29; NMS-873; PF-03758309; Telatinib